SN-38

SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) [1][2][3][4][5].

Product Specifications

CAS Number

[86639-52-3]

Product Name Alternative

7-Ethyl-10-hydroxycamptothecin

UNSPSC

12352005

Hazard Statement

H301

Target

ADC Payload; Autophagy; Drug Metabolite; Topoisomerase

Type

Natural Products

Related Pathways

Antibody-drug Conjugate/ADC Related; Autophagy; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SN-38.html

Purity

99.94

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C(CC)C5=CC(O)=CC=C5N=C4C3=C2)=O

Molecular Formula

C22H20N2O5

Molecular Weight

392.40

Precautions

H301

References & Citations

[1]Wallin A, et al. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep. 2008 Jun;19 (6) :1493-8.|[2]Jensen NF, et al. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a newpair of resistance-associated mutations. J Exp Clin Cancer Res. 2016 Mar 31;35:56.|[3]Kawato Y, et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51 (16) :4187-4191.|[4]Aaron T Jacobs, et al. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol. 2022 Oct:204:115209.